RPRXRoyalty Pharma plc
Is the price fair?
A demanding price: at the top of its own P/E range and rich vs its sector.
Expensive vs its own history: P/E 34.0 vs a 22.6 median over 22 quarters (+50% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What RPRX's price assumes
Royalty Pharma plc trades at 34.0× earnings against 19.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 19.8 · 1.72× the median: the market pays up for this one
- Price / sales
- 14.5
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 3.75
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 17.7
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 3.75
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 29.7
- EV / salestoday's price, trailing year to Jun 30, 2026
- 17.7
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Market capitalisation575.0 million shares, counted Jul 31, 2026
- $36.7B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $29.23 |
| Its own P/E history, median | $42.49 |
| Its own P/E history, upper quartile | $59.21 |
| 52-week range | $35.86 – $63.98 |
| Today | $63.84 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.